B7-H3 expression in children with asthma exacerbation
Background:
Recent studies have shown that B7-H3, a recently identified B7 family member, plays a critical role in the development of asthma.
Objective:
This study is to explore the expression of B7-H3 in children with asthma exacerbation.
Methods:
Twenty-one Chinese children with asthma exacerbation as well as 18 nonasthmatic control Chinese children were enrolled. B7-H3 level and cytokines (interferon [IFN]-γ, interleukin [IL]-4, and IL-10) determination were performed by enzyme-linked immunosorbent assay (ELISA) technique. Meanwhile, clinical parameters including laboratory findings, forced expiratory volume in one second (FEV1) and fractional exhaled nitric oxide were obtained.
Results:
Children with asthma exacerbation had significantly higher levels of B7-H3 than controls (4.46 ± 1.33 versus 3.42 ± 1.48 ng/mL; p = 0.027). Plasma IL-4 level was significantly higher in asthma exacerbation subjects than controls (157.98 ± 21.57 versus 121.92 ± 24.37 pg/mL; p < 0.0001), and IFN-γ level was significantly lower in asthma exacerbation subjects (292.73 ± 152.47 versus 421.78 ± 145.84 pg/mL; p = 0.0107). Level of B7-H3 in asthma exacerbation subjects with inhaled corticosteroid (ICS) treatment recently was significantly lower than subjects without ICS treatment (t = 2.706; p = 0.0136). Additionally, levels of B7-H3 decreased remarkably after prednisone treatment. Level of sB7-H3 in asthma exacerbation subjects was inversely correlated with level of IFN-γ (rp = −0.605; p = 0.005) after adjustment.
Conclusion:
B7-H3 may play an important role in asthma exacerbation and was a useful clinical biomarker to evaluate asthma exacerbation.
Recent studies have shown that B7-H3, a recently identified B7 family member, plays a critical role in the development of asthma.
Objective:
This study is to explore the expression of B7-H3 in children with asthma exacerbation.
Methods:
Twenty-one Chinese children with asthma exacerbation as well as 18 nonasthmatic control Chinese children were enrolled. B7-H3 level and cytokines (interferon [IFN]-γ, interleukin [IL]-4, and IL-10) determination were performed by enzyme-linked immunosorbent assay (ELISA) technique. Meanwhile, clinical parameters including laboratory findings, forced expiratory volume in one second (FEV1) and fractional exhaled nitric oxide were obtained.
Results:
Children with asthma exacerbation had significantly higher levels of B7-H3 than controls (4.46 ± 1.33 versus 3.42 ± 1.48 ng/mL; p = 0.027). Plasma IL-4 level was significantly higher in asthma exacerbation subjects than controls (157.98 ± 21.57 versus 121.92 ± 24.37 pg/mL; p < 0.0001), and IFN-γ level was significantly lower in asthma exacerbation subjects (292.73 ± 152.47 versus 421.78 ± 145.84 pg/mL; p = 0.0107). Level of B7-H3 in asthma exacerbation subjects with inhaled corticosteroid (ICS) treatment recently was significantly lower than subjects without ICS treatment (t = 2.706; p = 0.0136). Additionally, levels of B7-H3 decreased remarkably after prednisone treatment. Level of sB7-H3 in asthma exacerbation subjects was inversely correlated with level of IFN-γ (rp = −0.605; p = 0.005) after adjustment.
Conclusion:
B7-H3 may play an important role in asthma exacerbation and was a useful clinical biomarker to evaluate asthma exacerbation.
Keywords: Asthma exacerbation; B7-H3; children; cytokines
Document Type: Research Article
Affiliations: Department of Respiratory Disease, Soochow University Affiliated Children’s Hospital, Soochow University, Suzhou, China
Publication date: 01 July 2015
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content